Vifor Pharma (OTCPK:GNHA.F) - Aktienkurs, Nachrichten und Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

GNHA.F Aktienübersicht

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.

Über das Unternehmen

GNHA.F grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	4/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	6/6
Dividenden	3/6

Belohnungen

Trading at 45.4% below our estimate of its fair value

Earnings are forecast to grow 42.28% per year

Earnings have grown 16.3% per year over the past 5 years

Risikoanalyse

Shares are highly illiquid

Latest financial reports are more than 6 months old

Vifor Pharma AG Wettbewerber

Royalty Pharma

NasdaqGS:RPRX

US$16.4b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$6.7b

Organon

NYSE:OGN

US$4.9b

Corcept Therapeutics

NasdaqCM:CORT

US$4.4b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Vifor Pharma
Historische Aktienkurse
Aktueller Aktienkurs	CHF 181.25
52-Wochen-Hoch	CHF 183.50
52-Wochen-Tief	CHF 112.75
Beta	1.2
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	31.53%
33 Jahre Veränderung	17.70%
5 Jahre Veränderung	n/a
Veränderung seit IPO	20.90%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	GNHA.F	US Pharmaceuticals	US Markt
7D	0%	-1.4%	0.6%
1Y	31.5%	22.2%	32.1%

Rendite im Vergleich zur Industrie: GNHA.F exceeded the US Pharmaceuticals industry which returned 6% over the past year.

Rendite vs. Markt: GNHA.F exceeded the US Market which returned -23.7% over the past year.

Preisvolatilität

Is GNHA.F's price volatile compared to industry and market?
GNHA.F volatility
GNHA.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: GNHA.F has not had significant price volatility in the past 3 months.

Volatilität im Zeitverlauf: Insufficient data to determine GNHA.F's volatility change over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1872	2,200	n/a	www.viforpharma.com

Vifor Pharma AG's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Vifor Pharma im Vergleich zum Marktanteil des Unternehmens?
GNHA.F grundlegende Statistiken
Marktanteil	US$11.71b
Gewinn(TTM)	US$146.49m
Umsatz(TTM)	US$1.81b

79.9x

Kurs-Gewinn-Verhältnis

6.5x

Kurs-Umsatz-Verhältnis

Ist GNHA.F zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
GNHA.F Gewinn- und Verlustrechnung (TTM)
Einnahmen	CHF 1.81b
Kosten der Einnahmen	CHF 671.80m
Bruttogewinn	CHF 1.14b
Sonstige Ausgaben	CHF 993.70m
Umsatz	CHF 146.60m

Zuletzt gemeldete Gewinne

Dec 31, 2021

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	2.26
Bruttomarge	62.93%
Nettogewinnspanne	8.09%
Schulden/Eigenkapital-Verhältnis	13.6%

Wie hat sich GNHA.F auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.1%

Aktuelle Dividendenrendite

88%

Ausschüttungsquote

This company has been acquired

GNHA.F Aktienübersicht

Belohnungen

Risikoanalyse

Vifor Pharma AG Wettbewerber

NasdaqGS:RPRX

US$16.4b

NasdaqGS:JAZZ

US$6.7b

NYSE:OGN

US$4.9b

NasdaqCM:CORT

US$4.4b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Recent updates

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

Vifor Pharma Announces Board Changes

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Vifor Pharma AG's Grundlagenzusammenfassung

79.9x

6.5x

Erträge &amp; Einnahmen

Dividenden

1.1%

88%

Erträge & Einnahmen